ClinicalTrials.gg
CompletedNCT04231747Updated May 20, 2024

A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

A Phase 1 interventional study of CC-97540 in Lymphoma Non-Hodgkin, Agressive Lymphoma and Diffuse-large B-cell Lymphoma (DLBCL), sponsored by Juno Therapeutics, a Subsidiary of Celgene. Completed at 14 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-20.

Primary conditionLymphoma, B-CellRegistry: Lymphoma, Non-HodgkinReclassifiedWhy we changed it
Registry
Lymphoma, Non-Hodgkin — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, B-Cell
Why
  1. The study's listed conditions name Lymphoma, B-Cell, a narrower term within Lymphoma, Non-Hodgkin.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Juno Therapeutics, a Subsidiary of Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2024, 2 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Lymphoma, B-Cell by Bristol-Myers Squibb — none open to participants now, 2 under way, none of them phase 3. Lymphoma, B-Cell · Bristol-Myers Squibb.

Enrollment
9th of 10
24 · median 105
Started
2020
with 1 other
Phase 1
5 of 10
none open now
Registered
7th of 10
by date

Among the 10 studies in Lymphoma, B-Cell by Bristol-Myers Squibb, this one is the 9th largest by enrollment, is one of 2 that started in 2020, is one of 5 in phase 1, and was the 7th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

None of the 10 studies in Lymphoma, B-Cell by Bristol-Myers Squibb is open now. The open studies under Lymphoma, B-Cell, anywhere →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Lymphoma, B-Cell by Bristol-Myers Squibb as a file.
02

Study summary

This is a Phase 1, first-in-human, open-label, multicenter study of CC-97540, CD19-targeted NEX-T chimeric antigen receptor (CAR) T cells, in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma.

The study will consist of 2 parts: dose-escalation (Part A) and dose-expansion (Part B). The dose-escalation part (Part A) of the study is to evaluate the safety and tolerability of increasing dose levels of CC-97540 to establish a recommended Phase 2 dose (RP2D); and the dose-expansion part (Part B) of the study is to further evaluate the safety, pharmacokinetics/pharmacodynamics, and efficacy of CC-97540 at the RP2D.

03

Conditions studied

  • Lymphoma Non-Hodgkin
  • Agressive Lymphoma
  • Diffuse-large B-cell Lymphoma (DLBCL)

Browse trials for

Keywords

  • Lymphoma
  • B-cell non-Hodgkin lymphoma
  • Agressive Lymphoma
  • Diffuse-large B-cell Lymphoma
  • DLBCL
  • NHL
  • CC-97540
  • CD19
  • NEX-T chimeric antigen receptor (CAR) T cells
  • CAR-T
  • CART
04

In context

Lymphoma, B-Cell Reclassified

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

This study's enrollment of 24 is below the median of 34 across 773 interventional studies indexed under Lymphoma, B-Cell.

Browse Lymphoma, B-Cell studies →

Lead sponsor

Juno Therapeutics, a Subsidiary of Celgene is the lead sponsor of 12 studies on the registry; 1 is open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

First submitted after Juno Therapeutics, Inc. became part of Bristol-Myers Squibb.

Compared within Lymphoma, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma, Non-Hodgkin. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must satisfy the following criteria to be enrolled in the study:

  1. Age ≥ 18 years at the time of .
  2. Signed written informed consent obtained prior to any study procedure.
  3. Willing and able to adhere to the study visit schedule and other protocol requirements.
  4. aggressive B-cell NHL as defined:

    1. confirmed DLBCL not otherwise specified, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology (HGBCL), transformed DLBCL from follicular (tFL) or marginal zone lymphoma (tMZL), primary mediastinal B-cell lymphoma (PMBCL), or FL grade 3b (FL3B) (Note: Subjects with Richter's transformation (transformed DLBCL from CLL) are ineligible) AND
    2. Have relapsed and/or refractory disease after at least 2 which must include at least one anthracycline and rituximab (or other anti-CD20 monoclonal antibody).

      Note: Lines of therapy will exclude those given for prior indolent lymphoma. It is not required for subjects to have had anthracycline for their DLBCL if received for indolent disease AND/OR

    3. Have relapsed and/or refractory DLBCL failed to treatment. Note: ASCT failure is defined as either failure to achieve an objective response (PR or better), or disease progression after ASCT(Note: Subjects who were not candidates to receive ASCT treatment (due to age or other factors) are eligible; the reason for not receiving ASCT must be documented in the electronic case report form (eCRF).
  5. Positron emission tomography (PET)-positive disease as per the Lugano Classification (at screening or following bridging therapy, whichever is later).
  6. (ECOG) performance status of 0 or 1.
  7. Adequate organ function as detailed in the protocol.
  8. Adequate vascular access for leukapheresis.
  9. Willing and able to undergo tumor (in subjects with accessible disease).
  10. Agree to not donate blood, organs, sperm or semen, and egg cells for usage in other individuals as detailed in the protocol.
  11. Female and male subjects agree to use effective as detailed in the protocol.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a subject from enrollment:

  1. Uncontrolled medical, psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol, as judged by the Investigator; or unwillingness or inability to follow the procedures required in the protocol.
  2. Any condition including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study.
  3. Any condition that confounds the ability to interpret data from the study.
  4. Central nervous system (CNS)-only involvement by (note: subjects with -confirmed secondary CNS involvement are allowed).)
  5. Prior CAR T- cell or genetically-modified T- cell therapy, or prior CD19- targeted therapy (including, but not limited to, anti-CD19 mAbs or bispecific antibodies).)
  6. Treatment with the following therapies or procedure within the specified period:

    1. Therapeutic doses of (defined as > 20 mg/day prednisone or equivalent) within 14 days before leukapheresis administration. Physiologic replacement, topical, and inhaled steroids are permitted.
    2. Cytotoxic chemotherapeutic agents (eg, doxorubicin, vincristine, gemcitabine, oxaliplatin, carboplatin, etoposide) within 7 days of leukapheresis, with the exception of alkylating agents.
    3. Intrathecal therapy (eg, dexamethasone, methotrexate, cytosine arabinoside, cytarabine) within 7 days of leukapheresis.
    4. Oral chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at least 5 half-lives have elapsed prior to leukapheresis.
    5. Alkylating agents (eg, cyclophosphamide, ifosfamide, bendamustine) within 4 weeks of leukapheresis.
    6. Any experimental therapy within 8 weeks (for biologics) or 5 half-lives (for small molecules) before leukapheresis
    7. therapies within 4 weeks of leukapheresis (eg, calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, immunosuppressive antibodies such as anti-TNF, anti-IL6, or anti-IL6R)
    8. Monoclonal antibodies (including rituximab, polatuzumab, etc.) within 7 days.
    9. Donor lymphocyte infusions within 6 weeks of leukapheresis
    10. Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion, if additional non-irradiated PET-positive lesions are present, is allowed up to 14 days prior to leukapheresis.
    11. stem-cell transplant (SCT) (ie, Day 0 receipt of hematopoietic stem cells) within 3 months of leukapheresis
    12. Washout of prior therapy (eg, bridging therapy for disease control)
  7. Active disease requiring immunosuppressive therapy.
  8. Allogenic SCT (ie, Day 0 receipt of hematopoietic stem cells) within 6 months of leukapheresis or presence of ongoing symptoms or treatment for chronic (GVHD).)
  9. to fludarabine and/or cyclophosphamide.
  10. Prior history of malignancies, other than studied NHL, unless the subject has been free of the disease for ≥ 2 years except for the following non-invasive malignancies:

    1. Basal or squamous cell carcinoma of the skin
    2. Carcinoma in situ of the cervix or the breast
    3. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM (tumor, nodes, ) clinical staging system) or prostate cancer that is curative
    4. Other completely resected stage 1 solid tumor with low risk for recurrence
  11. Active , , or any (HIV) infection at the time of screening.
  12. Uncontrolled or active systemic fungal, bacterial, viral or other infection despite appropriate anti-infection treatment at the time of leukapheresis or pre-treatment evaluation.
  13. History of any one of the following cardiovascular conditions within the 6 months prior to screening: Class III or IV heart failure as defined by the , myocardial infarction, unstable angina, angioplasty or stenting, or other cardiac disease.
  14. History or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, or cerebellar disease. Presence of clinically active psychosis.
  15. History of ≥ Grade 2 hemorrhage within 30 days of screening.
  16. Pregnant or nursing (lactating) women.
  17. Previous SARS-CoV-2 infection within 10 days for mild or asymptomatic infections or 20 days for severe/critical illness prior to leukapheresis or initiation of LD chemotherapy.

    -Acute symptoms must have resolved and based on investigator assessment in consultation with the Sponsor Medical Monitor, there are no sequelae that would place the subject at a higher risk of receiving study treatment.

  18. Previous SARS-CoV-2 vaccine within 14 days prior to leukapheresis or initiation of LD chemotherapy.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    CC-97540 monotherapy

    Subjects will be assigned to receive CC-97540 followed by 3 consecutive doses of lymphodepleting chemotherapy (fludarabine IV (30 mg/m2/day) and cyclophosphamide IV (300 mg/m2/day).

    Biological: CC-97540

Interventions

  • BiologicalCC-97540

    Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) to produce CC 97540. During CC 97540 production, subjects may receive bridging chemotherapy for disease control. Upon successful generation of CC 97540 product, subjects will receive treatment with CC 97540 therapy. Each cycle will include lymphodepleting chemotherapy followed by one dose of CC 97540 administered by intravenous (IV) injection.

07

What researchers measure

Primary outcomes

  1. Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.ject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the sub

    Time frame: From the time of informed consent and follow up to 2 years after infusion of CC-97540

Secondary outcomes

  1. Complete Response Rate (CRR)

    The proportion of subjects with a best overall response of complete response (CR).

    Time frame: Up to 2 years after CC-97540 infusion

  2. Overall response Rate (ORR)

    The proportion of subjects achieving CR or partial response (PR).

    Time frame: Up to 2 years after CC-97540 infusion

  3. Duration of response (DOR)

    The time from first response to progressive disease (PD) or death.

    Time frame: Up to 2 years after CC-97540 infusion

  4. Time to response (TTR)

    Time from CC-97540 infusion to the first documentation of response (CR or PR).

    Time frame: Up to 2 years after CC-97540 infusion

  5. Time to complete response (TTCR)

    Time from CC-97540 infusion to the first documentation of CR

    Time frame: Up to 2 years after CC-97540 infusion

  6. Progression free survival (PFS)

    Time from CC-97540 infusion to the first documentation of PD, or death from any cause, whichever occurs first

    Time frame: Up to 2 years after CC-97540 infusion

  7. Overall survival (OS)

    Time from CC-97540 infusion to death

    Time frame: Up to 2 years after CC-97540 infusion

  8. Pharmacokinetics - peak expansion (Cmax)

    Maximum blood concentration

    Time frame: Up to 2 years after CC-97540 infusion

  9. Pharmacokinetics -time to peak expansion (tmax)

    Time to peak (maximum) blood concentration

    Time frame: Up to 2 years after CC-97540 infusion

  10. Pharmacokinetics - elimination half-life (t1/2)

    Elimination half-life

    Time frame: Up to 2 years after CC-97540 infusion

  11. Pharmacokinetics - Area under curve (AUC)

    Area under the curve

    Time frame: Up to 2 years after CC-97540 infusion

08

Study locations

14 sites
  • Local Institution - 003
    Birmingham, Alabama 35294-3300, United States
  • Local Institution - 004
    Atlanta, Georgia 30342, United States
  • Local Institution - 011
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
  • Nebraska Medicine Fred and Pamela Buffett Cancer Center
    Omaha, Nebraska 68105, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Local Institution - 001
    New York, New York 10021, United States
  • Local Institution - 008
    New York, New York 10065, United States
  • Local Institution - 010
    Charlotte, North Carolina 28204, United States
  • Oregon Health and Science University OHSU
    Portland, Oregon 97239, United States
  • Huntsman Cancer Institute - University of Utah
    Salt Lake City, Utah 84112, United States
  • Foothills Medical Centre - Tom Baker Cancer Centre
    Calgary, Alberta T2N 2T9, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 1C3, Canada
09

References and documents

Publications

  • Ernst M, Oeser A, Besiroglu B, Caro-Valenzuela J, Abd El Aziz M, Monsef I, Borchmann P, Estcourt LJ, Skoetz N, Goldkuhle M. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma. Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD013365. doi: 10.1002/14651858.CD013365.pub2. PubMed 34515338 ↗

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: https://www.celgene.com/research-development/clinical-trials/clinical-trials-data-sharing/

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: See Plan Description

Access criteria: See Plan Description

Data sharing details ↗ · www.celgene.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2020 to primary completion in Feb 2024, 44 months.

Of 90 industry-sponsored phase 1 interventional studies under Lymphoma, B-Cell, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 81. This study's 44 months is close to that.

Counting every sponsor, half of 207 studies reached it within 51 months; a quarter within 37 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 18, 2020
StartActual
May 21, 2020
Primary completionActual
Feb 1, 2024
CompletionActual
Feb 1, 2024
Last update
May 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04231747
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
May 21, 2020
Primary completion
Feb 1, 2024
Completion
Feb 1, 2024
Last update
May 20, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zolacabtagene autoleucel

Start the discussion